PE20150341A1 - Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona - Google Patents

Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona

Info

Publication number
PE20150341A1
PE20150341A1 PE2015000024A PE2015000024A PE20150341A1 PE 20150341 A1 PE20150341 A1 PE 20150341A1 PE 2015000024 A PE2015000024 A PE 2015000024A PE 2015000024 A PE2015000024 A PE 2015000024A PE 20150341 A1 PE20150341 A1 PE 20150341A1
Authority
PE
Peru
Prior art keywords
indol
lower alkyl
phenyl
pyrazino
dihydro
Prior art date
Application number
PE2015000024A
Other languages
English (en)
Spanish (es)
Inventor
Simona M Ceccarelli
Ravi Jagasia
Roland Jakob-Roetne
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20150341A1 publication Critical patent/PE20150341A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
PE2015000024A 2012-08-06 2013-08-05 Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona PE20150341A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12179381 2012-08-06

Publications (1)

Publication Number Publication Date
PE20150341A1 true PE20150341A1 (es) 2015-02-28

Family

ID=48918402

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000024A PE20150341A1 (es) 2012-08-06 2013-08-05 Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona

Country Status (24)

Country Link
US (1) US9284321B2 (enExample)
EP (1) EP2880036B1 (enExample)
JP (1) JP5974177B2 (enExample)
KR (1) KR101716062B1 (enExample)
CN (1) CN104540829B (enExample)
AR (1) AR092041A1 (enExample)
AU (1) AU2013301577B2 (enExample)
BR (1) BR112015000313A2 (enExample)
CA (1) CA2880682A1 (enExample)
CL (1) CL2015000143A1 (enExample)
CO (1) CO7141435A2 (enExample)
CR (1) CR20140545A (enExample)
EA (1) EA025884B1 (enExample)
IL (1) IL236808B (enExample)
MA (1) MA37791B1 (enExample)
MX (1) MX362184B (enExample)
MY (1) MY185216A (enExample)
NZ (1) NZ703192A (enExample)
PE (1) PE20150341A1 (enExample)
PH (1) PH12015500059B1 (enExample)
SG (1) SG11201408529VA (enExample)
TW (1) TWI506027B (enExample)
UA (1) UA113013C2 (enExample)
WO (1) WO2014023674A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913335T3 (es) * 2013-02-18 2022-06-01 Labrador Diagnostics Llc Análisis de imagen y medición de muestras biológicas
MX2015013915A (es) * 2013-04-02 2015-12-11 Hoffmann La Roche Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona.
RU2673489C2 (ru) * 2013-09-12 2018-11-27 Ф. Хоффманн-Ля Рош Аг Производные индолкарбоксамида

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1965981C3 (de) * 1968-02-13 1978-08-31 Sumitomo Chemical Co., Ltd., Osaka (Japan) 9-Phenyl-lO-oxopiperazino [l,2-a]-indole und Verfahren zu ihrer Herstellung
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
ATE448230T1 (de) * 2005-12-09 2009-11-15 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
WO2008046072A2 (en) 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
MX2009004898A (es) * 2006-11-09 2009-05-19 Hoffmann La Roche Derivados de indol y de benzofurano-2-carboxamida.
CA2804161A1 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
MX2015013915A (es) * 2013-04-02 2015-12-11 Hoffmann La Roche Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona.

Also Published As

Publication number Publication date
TW201410679A (zh) 2014-03-16
EP2880036B1 (en) 2017-03-08
EP2880036A1 (en) 2015-06-10
NZ703192A (en) 2016-04-29
JP2015524456A (ja) 2015-08-24
MX362184B (es) 2019-01-08
CL2015000143A1 (es) 2015-06-19
AU2013301577A1 (en) 2014-12-18
EA201590125A1 (ru) 2015-05-29
MX2015001318A (es) 2015-04-17
CO7141435A2 (es) 2014-12-12
TWI506027B (zh) 2015-11-01
US20150246922A1 (en) 2015-09-03
AR092041A1 (es) 2015-03-18
AU2013301577B2 (en) 2017-03-30
MY185216A (en) 2021-04-30
JP5974177B2 (ja) 2016-08-23
BR112015000313A2 (pt) 2017-06-27
MA37791A1 (fr) 2016-05-31
EA025884B1 (ru) 2017-02-28
PH12015500059A1 (en) 2015-03-02
CN104540829A (zh) 2015-04-22
CN104540829B (zh) 2017-04-26
IL236808B (en) 2018-05-31
CR20140545A (es) 2015-01-12
UA113013C2 (uk) 2016-11-25
SG11201408529VA (en) 2015-01-29
KR20150027832A (ko) 2015-03-12
CA2880682A1 (en) 2014-02-13
WO2014023674A1 (en) 2014-02-13
KR101716062B1 (ko) 2017-03-13
HK1206355A1 (en) 2016-01-08
US9284321B2 (en) 2016-03-15
MA37791B1 (fr) 2016-12-30
PH12015500059B1 (en) 2015-03-02

Similar Documents

Publication Publication Date Title
EA201301319A1 (ru) Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний
AR096640A1 (es) Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona
UY38953A (es) Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y composiciones farmacéu-ticas que las contienen
SG195085A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
MX375169B (es) Derivados de indolin-2-ona o pirrolo-piridin-2-ona.
PE20181272A1 (es) Heterociclilaminas como inhibidores de pi3k
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
AR082154A1 (es) DERIVADOS DE PIRAZOLO[1,5-a]PIRIMIDINA COMO MODULADORES DE IRAK4
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
AR104331A1 (es) Derivados de tetrazol
AR077960A1 (es) Derivados de benzamida n-sustituidos como inhibidores del transportador de glicina 1 (glyt-1)
AR081908A1 (es) N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas
PE20212113A1 (es) Inhibidores de moleculas pequenas de la familia de quinasas jak
PE20150341A1 (es) Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona
AR104863A1 (es) Derivados imidazol
AR099529A1 (es) Derivados de etinilo, un proceso para su fabricación; composiciones farmacéuticas que los comprenden y su uso en el tratamiento de enfermedades del sistema nervioso o cáncer
PE20141555A1 (es) Derivados de etinilo
CR20150158A (es) Derivados de etinilo como moduladores de receptor de actividad mglur5
AR107490A1 (es) Derivados de pirazol-piridina como inhibidores de eaat3
PE20201148A1 (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX374574B (es) Derivados indolin-2-ona y 1,3-dihidro-pirrol[3,2-c]piridin-2-ona.
PE20150685A1 (es) Pirimidinas de ariletinilo

Legal Events

Date Code Title Description
FG Grant, registration